Cardio Diagnostics Holdings, Inc. Announces 1-for-30 Reverse Stock Split
Cardio Diagnostics Holdings, Inc. (“Cardio” or the “Company”) (
NASDAQ: CDIO), today announced a 1-for-30 reverse stock split of its common stock effective with the market opening on May 13, 2025.
American Medical Association is Reviewing Cardio Diagnostics Holdings, Inc’s Integrated Epigenetic-Genetic Cardiovascular Medicine Tests for CPT PLA Codes
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, today announced the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel is reviewing its Epi+Gen CHD and PrecisionCHD tests for CPT Proprietary Laboratory Analyses (PLA) codes. If approved, the codes are expected to be published by the AMA by January 1, 2024, and will be effective on April 1, 2024. Obtaining CPT PLA codes would be a significant step towards securing federal and private payer reimbursement for the Epi+Gen CHD and PrecisionCHD tests.
